Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 37, Issue 2, 1998, Pages 221-227

  Kumra, S ^a   Jacobsen, L K ^a   Lenane, M ^a   Smith, A ^a   Lee, P ^a   Malanga, C J ^a   Karp, B I ^a   Hamburger, S ^a   Rapoport, J L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Childhood onset schizophrenia; Extrapyramidal side effects; Neuroleptics; Tardive dyskinesia; Withdrawal dyskinesia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0031885626     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199802000-00016     Document Type: Article

References (43)

1. J Alaghhand-Rad S Hamburger J Giedd J Frazier J Rapoport Childhood-onset schizophrenia: biological markers in relation to clinical characteristics Am J Psychiatry 154 1997 64 68
2. J Alaghhand-Kad K McKenna CT Gordon Childhood-onset Schizophrenia: the severity of premorhid course J Am Acad Child Adolesc Psychiatry 34 1995 1273 1283
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 3rd edition-revised (DSM-III-R) 1987 American Psychiatric Association Washington, DC
4. NC Andreasen Scale for the Assessment of Negative Symptoms (SANS) 1983 University of Iowa Iowa City
5. NC Andreasen Scale for the Assessment of Positive Symptoms (SAPS) 1984 University of Iowa Iowa City
6. RJ Baldessarini MH Teicher Dosing of antipsychotic agents in pediatric populations J Child Adolesc Psychopharmacol 5 1995 1 4
7. C Beasley G Tollefson P Tran W Satterlee T Sanger S Hamilton Olanzapine HGAD Study Group Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology 14 1996 111 123
8. M Campbell JL Arnienteros RP Malone PB Adams ZW Eisenberg JE Overall Ncuroleptic-related dyskinesias in autistic children: a prospective. longitudinal study J Am Acad Child Adolesc Psychiatry 36 1997 835 843
9. M Campbell D Grega W Green W Bennett Neuroleptic-induced dyskinesias in chiIdren Clin Neuropharmacol 6 1995 207 222
10. HE Cannon-Spoor SG Potkin RJ Wyatt Measurement of premorbid adjustment in chronic schizophrenia Schizophr Bull 8 1982 470 484
11. MH Chakos JM Alvir MG Woerner Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Arch Gen Psychiatry 53 1976 313 319
12. WS Fenton RJ Wyatt TH McGlashan Risk Factors for spontaneous dyskinesia in schizophrenia Arch Gen Psychiatry 51 1994 643 650
13. JA Frazier JN Giedd D Kaysen Childhood-onset schizophrenia: hrain MRI rescan after 2 years of clozapine maintenance treatment Am J Psychiatry 153 1996 564 566
14. W Guy Clinical Global Impression (CGI) ECDEU Assessment Manual 1976 US Department of Health, Education, and Welfare Washington. DC
15. Jacohsen LK, Rapoport JL (in press), Research update: childhood onset schizophrenia — implications of clinical and neurohiological research. J Child Psychcol Psychiatry
16. JM Kane Tardive dyskinesia: epidemiological and clinical presentation FE Bloom DJ Kupfer Psychopharmacology: The Fourth Generation of Progress 1905 Raven New York 14X5 I476
17. G Keepers V Clappison D Casey Initial anticholinergic prophylaxis for acute neuroleptic induced exrrapyramidal syndromes Arch Gen Psychiatry 40 1983 1113 1117
18. V Khot MF Egan TM Hyde RJ Wyatt Neuroleptics and classic tardive dyskinesia Drug-Induced Movement Disorders 1792 Futura Publishing Mount Kisco, NY 121 165
19. B Kufferle A Friedmann A Tpoitz Smooth pursuit eye movements in schizophrenia: influences of neuroleptic treatment and the question of specificity Psychopathology 23 1990 106 114
20. S Kumra J Frazier LK Jacobsen Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison Arch Gen Psychiatry 53 1996 1090 1097
21. S Kumra D Herion LK Jacobsen C Briguglia D Grothe Case study: risperidone-induced hepatotoxicity in pediatric patients J Am Acad Child Adolesc Psychiatry 36 1997 701 705
22. S Kumra LK Jacobsen M Lenane “Multidimensionally impaired disorder”: is it a variant of very early-onset schizophrenia? J Am Acad Child Adolesc Psychiatry 37 1998 91 99
23. Kumra S, Jacobsen LK, Lenane M et al. (in press), Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry
24. Y Levkovitch J Kronenberg N Kayser M Zvyvagelski B Gaoni N Gadoth Clozapine for tardive dyskinesia in adolescents. Brain Dew 17 1995 213 215
25. JA Lieberman BL Saltz CA Johns S Pollack M Borenstein J Kane The effects of clozapine on tardive dyskinesia Br J Psychiatry 158 1991 503 510
26. M Mandoki Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5 1995 49 67
27. K McKenna C Gordon M Lenane D Kaysen K Fahey J Rapoport Looking for childhood-onset schizophrenia: the first 71 cases screened J Am Acad Child Adolesc Psychiatry 33 1994 636 644
28. HY Meltzer Treatment of the neuroleptic-nonresponsive schizophrenic patient Schiwphr Bull 18 1992 515 542
29. H Orvaschel M Tabrizi W Chambers Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemioiogic Version (Kiddie-SADS-E) 3rd ed. 1980 Nova University Fort Lauderdale, FL
30. D Pool W Bloom D Mielke J Roniger D Gallant A controlled evaluation of Loxitane in seventy-fiveadolescent schizophrenic patients Curr Ther Res 19 1976 99 104
31. J Rapoport C Connors N Reatig Rating scales and assessment instruments for use in pediatric psychopharmacology research Psychopharmacol Bull 21 1985 713 1111
32. W Reich Z Welner DICA-RC (DSM-III-R Version), Revised Version, V-R 1988 Washington University St Louis
33. MA Richardson G Haughland TJ Craig Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients Am J Psychiatry 148 1991 1322 1328
34. NR Schooler JM Kane Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 39 1982 486 487
35. RR Silva HJ Magee AJ Friedhoff Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disorder J Child Adolesc Psychopharmacol 3 1973 137 144
36. G Simpson JSW Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand 212 suppl 1970 9 11
37. EK Spencer V Kafantaris MV Padron-Gayol CR Rosenberg M Campbell Haloperidol in schizophrenic children: early findings from a study in progress Psychopharmacol Bull 28 1992 183 186
38. S Szymanski J Lieberman S Pollack Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics Biol Psychiatry 39 1996 249 254
39. JL Waddington Spontaneous orofacial movements induced by rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology, and putative relationship to tardive dyskinesia Psychopharmacology 101 1990 431 437
40. JL Waddington EO O'Callaghan P Buckley Tardive dyskinesia in schizophrenia: relationship to minor physical anomalies, frontal lobe dysfunction, and cerebral structure on magnetic resonance imaging Br J Psychiatry 167 1995 41 44
41. DV Wolf KD Wagner Tardive dyskinesia, tardive dystonia, and tardive Tourette's syndrome in children and adolescents J Child Adolesc Psychopharmacol 3 1993 175 198
42. PE Yarden WJ Discipio Abnormal movements and prognosis in schizophrenia Am J Psychiatry 128 1971 317 323
43. M Zax A Sameroff H Babigian Birth outcomes in the offspring of mentally disordered women Am J Orrhopsychiatry 47 1977 218 230